Media
 

Noorik completes Phase IIa study of N-003 (ambrisentan) in patients with cirrhosis and history of ascites

February 16, 2018 - Basel, Switzerland

Noorik Biopharmaceuticals Ltd., a Swiss biopharmaceutical company developing N-003 (ambrisentan) as a novel therapeutic for the treatment of portal hypertension, announced the completion of its second clinical study.

In this Phase IIa study, subjects with cirrhosis and a history of ascites received N-003 at several, different doses while hospitalised. The key study objectives were to evaluate the safety of N-003, its pharmacokinetic profile and its effect on renal function.

The successful completion of this phase IIa represents a milestone in the development of N-003. Based on these positive findings, a Phase IIb study will be initiated to evaluate the effect of N-003 (ambrisentan) on portal pressure as determined by the Hepatic Venous Pressure Gradient (HVPG) in patients with cirrhosis and a history of refractory ascites. The study is expected to start later in 2018.

Noorik initiates Phase IIa study of N-003 (ambrisentan) in patients with cirrhosis and history of ascites

November 16, 2016 - Basel, Switzerland

Noorik Biopharmaceuticals Ltd., a Swiss biopharmaceutical company developing N-003 (ambrisentan) as a novel therapeutic for the prevention and treatment of acute renal failure and hepatorenal disorders, announced the start a Phase IIa study of N-003 (ambrisentan) in patients with cirrhosis and a history of ascites.

In this Phase IIa study, up to 32 subjects with a cirrhosis and a history of ascites will receive N-003 at several, different doses while hospitalised. The key study objectives are to evaluate the safety of N-003, its pharmacokinetic profile and its effect on renal function.

Noorik completes Phase I study of N-003 in healthy volunteers and readies Phase II investigation

July 25, 2016 - Basel, Switzerland

Noorik Biopharmaceuticals Ltd., a Swiss biopharmaceutical company developing N-003 as a novel therapeutic for the prevention and treatment of acute renal failure and hepatorenal disorders, announced the early completion of its first clinical study with N-003.

In this Phase I study, twenty healthy subjects received N-003 at several, different doses while hospitalised in a clinical pharmacology unit. The key study objectives were to evaluate the safety of N-003, its pharmacokinetic profile and its effect on renal function.

N-003 proved to be safe and well tolerated with all subjects completing the study as planned. Furthermore, results from this investigation have clearly confirmed the anticipated pharmacodynamic and clinical effects of N-003 on renal function in humans.

The successful completion of this phase I represents a milestone in the development of N-003. Based on these positive findings, therapeutic studies in the true target patient population can now be initiated. This Phase II study of N-003 in patients with advanced liver disease and renal dysfunction is expected to start later in 2016.

Noorik initiates Phase I study of N-003 in healthy volunteers

April 15, 2016 - Basel, Switzerland

Noorik Biopharmaceuticals Ltd., a Swiss biopharmaceutical company innovating therapeutics for acute renal failure, today announced the initiation of its first clinical study with N-003.

In this Phase I study, the pharmacokinetic and pharmacodynamic profile of N-003 will be evaluated in 20 healthy volunteers. This study will also provide preliminary safety and tolerability data to support future studies in the target diseases. The study will be conducted in Spain and is expected to be completed by June 2016.

Noorik Strengthens Board with Appointment of Pharmaceutical Veteran Mr. Elmar Schnee

July 1, 2015 - Basel, Switzerland

Noorik Biopharmaceuticals Ltd., a Swiss biopharmaceutical company innovating therapeutics for acute renal failure, today announced the appointment of Mr. Elmar Schnee as Chairman of the Board of Directors.

Mr Schnee holds both a bachelor’s degree in marketing and a master’s degree in marketing and general management from the Swiss Institute of Business Administration in Zürich. From 2003 to 2011, Mr. Schnee held various positions at Merck KGaA. He joined Merck in 2003 as Managing Director of Merck Santé S.A.S. and was appointed appointed as Deputy Member of the Executive Board responsible for the pharmaceuticals business in 2005. He became a Member of the Executive Board and General Partner of Merck KGaA in 2006, with responsibility for global pharmaceutical activities, and served in this position until 2011. Prior to Merck, Mr. Schnee held senior positions in strategy, business development and marketing at UCB SA, Sanofi-Synthélabo SA, Migliara/Kaplan Associates, Inc. and Fisons Pharmaceutical PLC. Mr. Schnee is a member of the board of directors of Jazz Pharmaceuticals plc and currently serves on the board of directors of three privately-held life sciences companies.